Common grade @ or @ adverse events included hypertriglyceridaemia ( @ -LSB- @ % -RSB- ) , fatigue ( @ -LSB- @ % -RSB- ) , hypertension ( @ -LSB- @ % -RSB- ) , and diarrhoea ( @ -LSB- @ % -RSB- ) in the dovitinib group , and hypertension ( @ -LSB- @ % -RSB- ) , fatigue ( @ -LSB- @ % -RSB- ) , dyspnoea ( @ -LSB- @ % -RSB- ) , and palmar-plantar erythrodysaesthesia ( @ -LSB- @ % -RSB- ) in the sorafenib group .